SCHEMBL16610341

SCHEMBL16610341

CC(C)CNC(=O)c1cc(O)c(O)c(C(F)(F)F)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.51
GAA P10253 2/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.49
HPGD P15428 2/20 0.44
HDAC4 P56524 1/20 0.43
KDM4E B2RXH2 3/20 0.42
LMNA P02545 3/20 0.41
HTT P42858 2/20 0.41
TACR1 P25103 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
NSD2 O96028 1/20 0.40
ALDH1A1 P00352 1/20 0.40
ALPL P05186 1/20 0.40
POLB P06746 1/20 0.40
ALPI P09923 1/20 0.40
MAPT P10636 1/20 0.40
ALPG P10696 1/20 0.40
APEX1 P27695 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206991 0.85 GAA (0.61) MLYCDGAAKMT2AHSD17B10HPGD
SCHEMBL497118 0.79 GAA (0.54) MLYCDGAAKMT2AHSD17B10HPGD
SCHEMBL16610364 0.76 GAA (0.46) GAAKMT2AHPGDLMNAPOLB
SCHEMBL2908793 0.76 HSD17B10 (0.78) MLYCDGAAKMT2AHSD17B10HPGD
SCHEMBL28012614 0.75 TRPV1 (0.52) HPGDKDM4EALDH1A1POLB
SCHEMBL16610336 0.75 TRPV1 (0.52) HPGDKDM4EALDH1A1POLB
SCHEMBL15653753 0.74 GAA (0.46) MLYCDGAAKMT2AHSD17B10HPGD
SCHEMBL5063742 0.72 GAA (0.58) MLYCDGAAKMT2AHSD17B10HPGD
SCHEMBL18082340 0.72 GAA (0.67) MLYCDGAAKMT2AHSD17B10HPGD
SCHEMBL18748508 0.72 GAA (0.62) MLYCDGAAKMT2AHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3409664-B1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS TASLY PHARMACEUTICAL GROUP CO (CN) 2021-01-06 EP claimed
US-20190046500-A1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-02-14 US claimed
EP-3409664-A1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS Tasly Pharmaceutical Group Co., Ltd. (CN) 2018-12-05 EP claimed
CN-104513172-A Trifluoromethyl-containing amide alkaloids, and preparation method and drug use thereof TASLY PHARMACEUTICAL GROUP CO 2015-04-15 CN claimed
CN-107011313-B Application of substituted cinnamide derivative in preparation of anxiolytic drugs 天士力医药集团股份有限公司 2021-11-30 CN disclosed
EP-3409664-B1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS TASLY PHARMACEUTICAL GROUP CO (CN) 2021-01-06 EP disclosed
EP-3409664-B1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS TASLY PHARMACEUTICAL GROUP CO (CN) 2021-01-06 EP disclosed
US-10874636-B2 Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-12-29 US disclosed
US-10874636-B2 Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) 2020-12-29 US disclosed
US-20190046500-A1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-02-14 US disclosed
US-20190046500-A1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION TASLY PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-02-14 US disclosed
EP-3409664-A1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATIONS Tasly Pharmaceutical Group Co., Ltd. (CN) 2018-12-05 EP disclosed
CN-104513172-A Trifluoromethyl-containing amide alkaloids, and preparation method and drug use thereof TASLY PHARMACEUTICAL GROUP CO 2015-04-15 CN disclosed
WO-2015043522-A1 TRIFLUOROMETHYL-CONTAINING AMIDE ALKALOID, MANUFACTURING METHOD AND PHARMACEUTICAL USE THEREOF 天士力制药集团股份有限公司 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874636-B2 Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication CBR3, CYP4F3, CYP4F2 MLYCD 1444/4885GAA 3368/4885KMT2A 1181/4885
US-20190046500-A1 APPLICATION OF SUBSTITUTED CINNAMAMIDE DERIVATIVES IN PREPARATION OF ANTI-ANXIETY MEDICATION CBR3, CYP4F3, CYP4F2 MLYCD 1444/4885GAA 3368/4885KMT2A 1181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.